PPARG and breast cancer: These data coincide with findings in several in vivo and in vitro studies in which PPARγ agonists such as rosiglitazone or troglitazone decreased proliferation of breast cancer cell lines, mediated in part by a PPARγ-dependent mechanism [26], [56].